Table 1.
Composition of the 13 peptide mixes screened in this study.
| Name | Amino acid sequence | Name | Amino acid sequence |
|---|---|---|---|
| Mix 1 | Mix 7 | ||
| Macrophage inhibitory factor | TKP | 7B2 (SCG5; Secretogranin-V) C-terminal peptide | SVPHFSEEEKEPE |
| Thyrotropin-releasing hormone precursor | QHP-NH2 | Neurotensin | pQLYENKPRRPYIL |
| Thyrotropin-releasing hormone | pQHP-NH2 | Apelin-13 | QRPRLSHKGPMPF |
| N-Tyr-Melanocyte-inhibiting factor (MIF-1) | YPLG-NH2 | Rimorphin | YGGFLRRQFKVVT |
| Angiotensin I/II(1–4) | DRVY | DynorphinA(1–13) | YGGFLRRIRPKLK |
| Endomorphin-1 | YPWF-NH2 | α-Melanocyte-stimulating hormone | SYSMEHFRWGKPV-NH2 |
| Leu-enkephalin | YGGFL | Pro-Melanin-concentrating hormone(131–144) | EIGDEENSAKFPIG |
| Met-enkephalin | YGGFM | Propeptide21–45(1–14) | QPVVPVEAVDPMEQ |
| long proCART(55–59) | IPIYE | Secretogranin I(186–199) | HTEESGEKHNAFSN |
| Angiotensin I/II(1–5) | DRVYI | Secretogranin II(599–612) | LNQEQAEQGREHLA |
| Mix 2 | Mix 8 | ||
| Tyr-FMRFamide | YFMRF-NH2 | WE-14 | WSRMDQLAKELTAE |
| Neuromedin-N | KIPYIL | Urotensin 2 | QHGTAPECFWKYCI |
| NT-2 (fragment analogue of neurotensin) | RKPWLL | Somatostatin 14 | AGCKNFFWKTFTSC |
| Angiotensin IV | VYIHPF | Secretogranin I(437–451) | DEGHDPVHESPVDTA |
| ORG2766 | (M-O)EHF(D-K)F | VGF(180–194) | pQQETAAAETETRTHT |
| Selank | TKPRPGP | Thymosin beta-10(30–44) | PTKETIEQEKRSEIS |
| KEP | ARPVKEP | Secretogranin II(598–612) | YLNQEQAEQGREHLA |
| ACTH(4–10) | MEHFRWG | [des-Ser1]-cerebellin | GSAKVAFSAIRSTNH |
| Angiotensin I/II(1–7) | DRVYIHP | BigLEN | LENSSPQAPARRLLPP |
| Propeptide 219–229(1–7) | VGRPEWW | VGF(220–235) | VPERAPLPPSVPSQFQ |
| Mix 3 | Mix 9 | ||
| Angiotensin III | RVYIHPF | Secretogranin III(38–53) | ELSAERPLNEQIAEAE |
| Met-enkephalin-RGL | YGGFMRGL | Cerebellin | SGSAKVAFSAIRSTNH |
| Substance P-like | RPQQFGLM -NH2 | Neuropeptide AF-like | AGEGLSSPFWSLAAPQR-NH2 |
| Dynorphin A(1–8) | YGGFLRRI | Thymosin beta-4(28–44) | PLPSKETIEQEKQAGES |
| Neuropeptide FF | FLFQPQRF-NH2 | Chromogranin A(377–393) | LEGEDDPDRSMKLSFRA |
| Angiotensin II | DRVYIHPF | Neuropeptide2 (NocII) | FSEFMRQYLVLSMQSSQ |
| Oxytocin | CYIQNCPLG-NH2 | Nociceptin | FGGFTGARKSARKLANQ |
| 7B2 (SCG5; Secretogranin-V) C-terminal peptide(5–13) | FSEEEKEPE | Dynorphin A(1–17) | YGGFLRRIRPKLKWDNQ |
| Secretogranin I(454–462) | YPQSKWQEQ | LittleSAAS | SLSAASAPLAETSTPLRL |
| Bradykinin | RPPGFSPFR | Tubulin beta-4B chain(168–185) | SVVPSPKVSDTVVEPYNA |
| Mix 4 | Mix 10 | ||
| Gonadotropin-releasing hormone-1-like | HWSYGLRPG | Octadecaneuropeptide | QATVGDVNTDRPGLLDL(K-Ac) |
| β-neoendorphin | YGGFLRKYP | Neuropeptide NPVF | ANMEAGTMSHFPSLPQRF-NH2 |
| Arg-vasopressin | CYFQNCPRG-NH2 | β-Melanocyte-stimulating hormone | ADGPYRVEHFRWGNPPKD |
| Angiotensin I(1–9) | DRVYIHPFH | Neuroendocrine regulatory peptide-4 | NAPPEPVPPPRAAPAPTHV |
| LittleLEN | LENSSPQAPA | Neuropeptide-GE | GPAVFPAENGVQNTESTQE |
| Secretogranin I(371–380) | SEESQEKEYP | long proCART(10–28) | ALDIYSAVDDASHEKELPR |
| HFHH-10 | HFHHALPPAR | LQEQ-19 | LQEQEELENYIEHVLLHRP |
| Antrin | APSDPRLRQF | ||
| Gonadotropin-releasing hormone-1 | pQHWSYGLRPG-NH2 | ||
| Substance P-like | RPKPQQFGLM-NH2 | ||
| Mix 5 | Mix 11 | ||
| α-neoendorphin | YGGFLRKYPK | VGF(211–217) | ASWGEFQ |
| Kisspeptin-10 | YNWNSFGLRY-NH2 | Cholecystokinin-8 | DYMGWMDF-NH2 |
| [Ser2]-Neuromedin-C | GSHWAVGHLM-NH2 | Neurokinin-B | DMHDFFVGLM-NH2 |
| Secretogranin-I (585–594) | SFAKAPHLDL | Proenkephalin 114–133(7–20) | VEPEEEANGGEILA |
| Neurokinin-A | HKTDSFVGLM-NH2 | Chromogranin A(377–391) | LEGEDDPDRSMKLSF |
| Angiotensin I | DRVYIHPFHL | β-Preprotachykinin | ALNSVAYERSAMQNYE |
| Chromogranin A derivative | AYGFRDPGPQL | Gastrin | pQRPPMEEEEEAYGWMDF |
| TLQP-11 (VGF-derived peptide) | TLQPPASSRRR | ||
| Neuropeptide AF-like (C-terminal part of AF) | EFWSLAAPQRF-NH2 | ||
| T-kinin | ISRPPGFSPFR | ||
| Mix 6 | Mix 12 | ||
| Substance P | RPKPQQFFGLM-NH2 | Tail peptide (potential) | ASYYY |
| Neuropeptide FF precursor | NPAFLFQPQRF-NH2 | β-casomorphin-7 | YPFPGP |
| γ-Melanocyte-stimulating hormone-like | YVMGHFRWDRF-NH2 | ||
| VGF(496–507) | PPPRAAPAPTHV | Mix 13 | |
| Somatostatin-28(1–12) | SANSNPAMAPRE | Met-enkephalin-RF | YGGFMRF |
| Cholecystokinin-12 | ISDRDYMGWMDF-NH2 | Urotensin-2B | ACFWKYCV |
| Neurotensin-like | LYENKPRRPYIL | Melanin-concentrating hormone | DFDMLRCMLGRVYRPCWQV |
| RFamide-related peptide-1 | VPHSAANLPLRF-NH2 | ||
| Obestatin-13(C-terminal fragment) | LSGAQYQQHGRAL-NH2 | ||
| Neuropeptide-EI | EIGDEENSAKFPI-NH2 | ||
Sequences of peptides are given in the one-letter code. ACTH, Adrenocorticotropic hormone; CART, Cocaine and amphetamine regulated transcript; pQ, pyro-glutamic acid; (M-O), methionine-sulfoxide; (D-K), D-lysine; (K-Ac), acetylated lysine. Sulfo- or phosphotyrosin modifications were not incorporated into peptides (peptides affected: Cholecystokinin-8, Kisspeptin-10, Cholecystokinin-12 and Gastrin). Incidentally, gastrin was not amidated at the C-terminus. Disulfide bridges were introduced in case of the following peptides: Oxytocin, Arg-Vasopressin, Urotensin-2 and Somatostatin-14.